Bioconversion studies conducted on the furanocoumarins angelicin and chalepensin have revealed that angelicin was metabolized by Lipomyces lipofer (ATCC 10742) to give the corresponding reduced acid 3 and chalepensin was transformed by Cunninghamella blakesleeana (SC-2138) to give the diol metabolite 4. The structures of the new metabolites have been established on the basis of spectral data. The absolute stereochemistry around C-2´´ in 4 was confirmed by Horeau's method. Angelicin and chalepensin were shown to possess antifungal activity against Candida albicans and Cryptococcus neoformans.
Furanocoumarins are known to possess interesting biological activities. For example, angelicin was shown to possess slight antifungal activity against Candida albicans, Cryptococcus neoformans, Cladosporium cucumerinum and Aspergillus niger [10, 11] . Angelicin was also shown to inhibit inducible nitric oxide synthase-dependent production of nitric oxide [12] . On the other hand, chalepensin was shown to exhibit antifertility activity in female rats [13] , and Ca 2+ channel blocking activity [14] .
The utilization of microbes as models for mammalian metabolism of xenobiotics has been well established since the early 1970s, when the idea was first introduced by Smith and Rosazza [15, 16] . This concept depends on the fact that fungi, being eukaryotes, possess metabolizing enzymatic machinery similar to those of mammals. Biocatalysis is also a documented method to generate unique, diverse, regioselective, active, and less toxic derivatives for lead optimization and to establish structure-activity relationships [15, 16] . Hence, it is anticipated that the microbial metabolism of 1 and 2 would produce significant quantities of metabolites that would be difficult to obtain from either animal systems or chemical synthesis. Moreover, this may provide some novel metabolites that may serve as starting compounds for the semi-synthesis of other derivatives, or as analytical standards for mammalian metabolic studies. (Table 1) . The presence of a broad absorption band at 3300 cm -1 and a strong absorption band at 1650 cm -1 in the IR spectrum suggested the conversion of the original angelicin lactone into phenol and carboxylic acid functionalities. indicated the reduction of the C-3,4 double bond. Except for the downfield shift of C-2 and the upfield shift of C-4a, the 13 C resonances remained the same as those of the starting material (Table 1 ). Furthermore, the 1 H NMR spectrum showed the conversion of the two doublets (δ 6.38, d, J = 9.5 Hz, H-3, and δ 7.79, d, J = 9.5 Hz, H-4) into a broad singlet at δ 2.37 (H-3) and a triplet at δ 2.76, J = 5.5
Hz (H-4).
HMBC data (Table 1) showed strong three-bond correlations between H-4 (δ 2.76, t, J = 5.5 Hz) and Table 2 . Other proton and carbon assignments were unambiguously made using COSY, HMQC and HMBC data.
4 #
The absolute stereochemistry around C-2´´ in 4 was concluded using Horeau's asymmetric esterification method [17, 18] . The result of this experiment indicated an S configuration, as suggested by the value of [α] D +1.85° of the partially resolved α-phenylbutyric acid. This was also consistent with the (+)-optical rotation of the known (S)-3,3-dimethylbutane-1,2-diol, an identical side chain to 4 [19] .
Angelicin was shown to possess an IC 50 value of 40 μg/mL against both Candida albicans ATCC 90028 and Cryptococcus neoformans ATCC 90113 and chalepensin was shown to have an IC 50 value of 50 μg/mL against C. albicans and be inactive against C. neoformans, while their metabolites were inactive against both yeasts in the antimicrobial activity assay. On the other hand, all compounds showed no promising in vitro anti-hepatitis B activity.
Experimental
The IR spectra were recorded in KBr disk using an ATI Mattson Genesis Series FTIR spectrophotometer. UV spectra were measured in methanol using a UV-160 IPC UV-visible dual-beam spectrophotometer. Optical rotations were taken with a Perkin-Elmer 241 MC polarimeter. The 1 H and 13 C NMR were obtained on a Bruker DRX-500 spectrometer operating at 500 and 125 MHz, respectively. Both 1 H and 13 C NMR spectra of 3 were recorded in DMSO-d 6 and in CDCl 3 for 4 and the chemical shift values were expressed in δ (ppm) relative to the internal standard TMS. For the 13 C NMR spectra, the number of attached protons was determined by DEPT 135°. 2D NMR spectroscopic data were obtained using the standard pulse sequence of the Bruker DRX-500 for COSY, HMQC, HMBC and NOESY. The HRMS spectra were measured on a Bioapex FTMS with electrospray ionization.
Cultures and fermentation screening procedure:
The microbial cultures were originally obtained from either the American Type Culture Collection (ATCC), Rockville, Maryland, or from the USDA Northern Regional Research Laboratories (NRRL), Peoria, Illinois, and are maintained in Kuwait University, Department of Pharmaceutical Chemistry Culture Collection. Stock cultures were maintained on agar slants of media recommended by the ATCC and were stored at 4°C.
All the preliminary screening and preparative-scale experiments were carried out as reported before [16] and according to a standard two-stage protocol [20] . Bullera alba ATCC 18568, Cunninghamella elegans ATCC 9245, Lipomyces lipofer ATCC 10742 and Rhizopus stolonifer ATCC 24795 showed metabolizing capabilities of 1 producing the common metabolite 3, and, thus, L. lipofer was selected for preparative-scale fermentation to produce metabolite 3. On the other hand, only Cunninghamella blakesleeana SC-2138 was shown to be able to bioconvert 2 into 4, and hence, was selected for large-scale fermentation. Substrates 1 and 2 were, separately, prepared as a 15% solution in N,Ndimethylformamide (DMF) and added to the 24-h-old stage II culture media of the respective microorganism at a concentration of 0.024 mg/mL of medium. Substrate controls were composed of sterile medium to which the substrate (4 mg/100 μL DMF) was added and incubated without microorganisms. Culture controls consisted of fermentation blanks in which the microorganisms were grown under identical conditions, but without the substrate addition. After two weeks of incubation, each control was harvested and analyzed by TLC.
Fermentation sampling and chromatographic conditions:
The fermentations were sampled by withdrawing 5 mL of culture and extracting it with 5 mL of CHCl 3 . The concentrated organic phase was analyzed by TLC for the presence of metabolites. TLC analyses were performed on precoated silica gel 60 F 254 (Merck) plates using 16% for substrate 1, and 8% for substrate 2, MeOH in CHCl 3 as the solvent system. Visualization was accomplished using UV light quenching at λ = 256 nm and then spraying with p-anisaldehyde spray reagent. The adsorbent used for column chromatography was Si gel 60/230-400 mesh (EM Science, Darmstadt). Angelicin (1) and chalepensin (2), the substrates used in this project, were isolated from Psoralea plicata (Leguminosae) and Ruta chalepensis (Rutaceae), respectively, as previously reported [21] . All solvents used for chromatographic purposes were reagent grade.
Preparative scale fermentation of angelicin by Lipomyces lipofer: L. lipofer ATCC 10742 was grown in ten 1L culture flasks each containing 200 mL of medium α. A total of 250 mg of angelicin (in 1.6 mL DMF) was evenly distributed among the 24-h-old stage II culture. After seven days, the incubation mixtures were checked by TLC to reveal that some of the angelicin had been transformed into one major metabolite.
After another week, the incubation mixtures were combined and filtered to remove the mycelia, and the filtrate was extracted with CHCl 3 (1.5 L x 4). The combined extracts were dried over anhydrous Na 2 SO 4 and evaporated to dryness in vacuo at 40 °C to afford a brownish residue (440 mg), which was purified by column chromatography over silica gel (44 g, 2.7 x 20 cm) using MeOH-CH 2 Cl 2 (1:19 v/v) as the eluting solvent system. Fractions of 20 mL each were collected and pooled on the basis of TLC analyses. Fractions 25-26 yielded about 50 mg of semi-pure 3, which were further purified over 50 g Sephadex LH20 using MeOH-CH 2 Cl 2 (1:1 v/v) for six fractions each of 20 mL, followed by 100% MeOH. Fractions 9-8 provided pure metabolite 3 (25 mg, 9.1% yield).
Preparative scale fermentation of chalepensin by Cunninghamella blakesleeana SC-2138: A total of 130 mg of chalepensin was dissolved in 0.85 mL of DMF and evenly distributed between twenty-three 250 mL culture flasks, each containing 50 mL of 24-h-old C. blakesleeana stage II culture. After six days, the incubation mixtures were checked by TLC to reveal that most of the chalepensin had been transformed into one major metabolite 4.
The incubation mixtures were combined and filtered to remove the mycelia, and the filtrate was extracted with CHCl 3 (1 L x 4) . The combined extracts were dried over anhydrous Na 2 SO 4 and evaporated to dryness in vacuo at 40°C to afford a yellowish residue (114 mg). This was purified by column chromatography over silica gel (30 g, 3.3 x 10 cm) using ethyl acetate-n-hexane (3:17 v/v) as the eluting solvent. Fractions 20-22 yielded semi-pure 4, which was further purified on preparative TLC plates using MeOH-CHCl 3 (1: 11) to give pure metabolite 4 (5.6 mg, 4.1% yield).
Horeau's method for the determination of the absolute configuration of 4: A solution of 10 mg of α-phenylbutyric anhydride in 0.5 mL dry pyridine was added to 2.5 mg of 4. The mixture was stirred for 24 h at room temperature. The solution was then extracted with EtOAc (5 mL x 3). The EtOAc extracts were washed twice with 5 mL 5% NaHCO 3 and finally with H 2 O (5 mL x 3). The residue (8 mg) contained no starting material, as indicated by TLC, suggesting 100% esterification. The combined aqueous extracts were washed with CHCl 3 (5 mL x 2) and then acidified with excess 1 N H 2 SO 4 . The acidified solution was extracted with CHCl 3 (5 mL x 2), dried and evaporated to dryness to afford 2.6 mg of α-phenylbutyric acid ([α] D +1.85°, from CHCl 3 , enantiomeric excess 27.6%).
Metabolite 3
[α] D : +2.22° (c 0.09, MeOH). R f : 0. 
